STOCK TITAN

Biomark Diagnostics Inc. - BMKDF STOCK NEWS

Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.

BioMark Diagnostics Inc. (BMKDF) is a clinical and diagnostic laboratory specializing in liquid biopsy molecular diagnostic tests for hard-to-detect and treat cancers. The company focuses on developing assays for measuring response to treatment and monitoring for recurrence in cancers like glioblastoma and lung cancer. With recent patent grants from the Canadian Intellectual Property Office and ongoing prospective clinical studies, BioMark is at the forefront of revolutionizing early detection and diagnosis of cancers using metabolomics and machine learning algorithms.

In addition to its core focus on lung cancer, BioMark plans to expand into detecting and treating brain, ovarian, and pancreatic cancers. The company's innovative approach to cancer diagnostics aims to improve cancer prognosis by allowing for early detection and personalized treatment, ultimately enhancing patient outcomes.

Rhea-AI Summary

BioMark Diagnostics Inc. (CSE: BUX) (OTC Pink: BMKDF) announced that collaborators from the University of Manitoba will present new research findings on glioblastoma at the 2024 GPEN Conference in Copenhagen. The presentations focus on:

1. Evaluation of hydrogel formulations for delivering siRNA to glioblastoma tumor cells
2. Examination of potential drug biomarker candidates for glioblastoma

The research highlights BioMark's liquid biopsy technology for evaluating minimal residual disease and treatment outcomes in glioblastoma. CEO Rashid Ahmed Bux emphasized their comprehensive approach, including biomarker discovery, novel drug delivery mechanisms, and potential gene knockdown treatments for glioblastoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-100%
Tags
none
-
Rhea-AI Summary
BioMark Diagnostics Inc. announces the extension of 5,062,000 non-broker warrants with an exercise price of C$0.45 until May 4th, 2026. The company also grants 4,625,000 stock options to key personnel at a purchase price of $0.45 per share, vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
Rhea-AI Summary
BioMark Diagnostics Inc. secures research funding for a cancer treatment study for Glioblastoma. The project aims to develop a drug delivery platform for improved radiation responses in various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
Rhea-AI Summary
BioMark Diagnostics Inc. and Rubix LS announce a strategic partnership to develop better diagnostic tools for lung and breast cancer screening, focusing on underserved communities. The collaboration aims to enhance early detection and personalized treatment for hard-to-detect cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
BioMark Diagnostics Inc. announces the addition of Theresa Peterson to its Advisory team. Peterson's expertise in funding opportunities and relationship-building is expected to enhance BioMark's growth and expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has closed a financing round, raising $1,900,000 for the commercialization of its liquid biopsy technology. The financing included a non-brokered private placement and a debt conversion. The company also received non-dilutive funding of CAD $231,000 from the City of Quebec. BioMark plans to introduce its early lung cancer diagnostics assay within the next 6-9 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) has been granted patent N° 2.906.236 by the Canadian Intellectual Property Office for their legacy assay 'Detection and Quantification of Acetylamantadine in Urine Sample.' The patent strengthens their metabolite measurement capabilities, expanding options to quantify the substrate of interest using Raman spectroscopy. The company is conducting clinical studies for measuring response to treatment for glioblastoma and advanced-stage lung cancer, with results expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioMark Diagnostics Inc. (BUX) reports strong operational results for the second quarter, with expanded technical team, new hires, and funding support for the launch of its early lung cancer assay in 2024. The company also announces an extension of the warrant exercise term to improve corporate value for its shareholders. The unaudited consolidated results show revenues of CA$81,872 for the six months ended September 30, 2023, and a 15% increase in Research & Development expenses compared to the same period last year. Cash, short-term, and long-term investments stood at C$632,238 as of September 30, 2023. The number of outstanding common shares was 83,286,229, with 12,534,579 stock options and warrants issued. The company intends to extend the term of non-broker warrants issued in relation to a private placement financing that closed on December 13, 2019, to December 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) announces the appointment of Dr. W. Randolph Ford to its Advisory team to enhance its data analytics and AI capabilities. Dr. Ford's expertise will support the commercial acceleration of BioMark's early cancer detection technology, with a focus on hard-to-detect and treat cancers. The company has seen a boost in its diagnostic assay performance by incorporating AI and sophisticated data analytic techniques provided by Dr. Ford. Exciting early breast detection data analysis will be presented at the upcoming San Antonio Breast Cancer Symposium. Dr. Ford's experience and connections will be invaluable as BioMark evolves into a commercial entity with strong AI and ML embedded capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
none
Rhea-AI Summary
BioMark Diagnostics Inc. has been awarded non-dilutive funding of CAD $231,000 from the City of Quebec to accelerate commercialization and market development activities of its proprietary assay for early detection of lung cancer. The company plans to use the funding to support business development and commercialization of its liquid biopsy assay for early cancer detection and treatment management, leveraging its Quebec-based fully equipped laboratory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none

FAQ

What is BioMark Diagnostics Inc. focused on?

BioMark specializes in developing liquid biopsy molecular diagnostic tests for hard-to-detect and treat cancers, with a current emphasis on lung cancer.

What recent achievement has BioMark Diagnostics Inc. made?

The company has received patent grants from the Canadian Intellectual Property Office for its assays measuring response to treatment and recurrence in cancers.

What are BioMark Diagnostics Inc.'s ongoing projects?

BioMark is conducting prospective clinical studies on measuring response to treatment for glioblastoma and advanced-stage lung cancer.

What is the long-term goal of BioMark Diagnostics Inc.?

The company aims to expand its liquid biopsy technology to detect and treat brain, ovarian, and pancreatic cancers, revolutionizing early cancer detection and diagnosis.

How does BioMark Diagnostics Inc. leverage metabolomics and machine learning algorithms?

By using advanced technologies, BioMark enhances cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages and measure response to treatment.

Biomark Diagnostics Inc.

OTC:BMKDF

BMKDF Rankings

BMKDF Stock Data

16.71M
39.17M
50.26%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Richmond